FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-05

Price

$14.33

+0.00%

Score3.5Watchlist

Signals3/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

FOLD is currently a 'Special Situation' rather than a traditional breakout, effectively pinned to its $14.50/share all-cash acquisition by BioMarin (BMRN). The 'Alpha Male' and 'Quiet Storm' signals are technical artifacts of Merger Arbitrage desks absorbing supply and pinning the price, creating a low-volatility line just below the deal cap. With shareholders approving the merger on March 3, 2026, and FTC early termination already granted, the stock is behaving as a defensive cash-substitute in a 'Caution' macro regime, immune to the broader geopolitical volatility.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBARGAIN HUNTER

Key Takeaways

**Deal Status:** Shareholders approved the BioMarin merger on March 3; FTC early termination granted Feb 11. Deal is highly likely to close in Q2 2026.
**The Trade:** This is an arbitrage play, not a growth trade. The current price ($14.33) offers a ~1.2% spread to the $14.50 closing price—effectively a low-risk yield.
**Signal Context:** The 'Quiet Storm' (Low Vol) and positive Relative Strength are due to the stock's decoupling from the S&P 500 beta, making it a 'Safe Haven' asset.

← Back to 2026-03-05 View Full FOLD History →Yahoo Finance &nearr;